Research projects and
cooperative projects
wissenschaftliche und kooperative Projekte
Real world effectiveness and safety of brexucabtagene autoleucel versus patient-individual therapy in relapsed/refractory mantle cell lymphoma
Status: Active
Type, Partner: Kite/Gilead
Year: 2023
Type of analysis: Aggregated
Late POD
Status: Active
Type, Partner: FIL, Visco
Year: 2022
Key parameters: Patients with positive disease course - characteristics
Type of analysis: Patient level
Fate of BTK-failures
Status: Active
Type, Partner: Lilly
Year: 2022
Type of analysis: Aggregated
Retrospective database research of real-world treatment patterns in Mantle Cell Lymphoma (MCL) patients in Germany, Italy and Europe
Status: Acitve
Type, Partner: Janssen
Year: 2022
Type of analysis: Aggregated
Retrospective analysis of real-world treatment patterns in Mantle Cell Lymphoma patients in Germany
Status: Active
Type, Partner: AbbVie
Year: 2022
Type of analysis: Aggregated
Prognosis of patients with Mantle Cell Lymphoma – Covid19
Status: Completed, follow up
Type, Partner: None
Year: 2022
Key parameters: Outcome of Covid-19- in patients with mantle cell lymphoma
Type of analysis: Internal analysis
Publication: DOI: 10.1097/HS9.0000000000000711
SCHOLAR 2: Ibrutinib Failure: Fate and health care utilization
Status: Completed
Type, Partner: Entity, Gilead
Year: 2019-2021
Key parameters: Outcome after BTKi-failure, Health care utilization
Type of analysis: Aggregated, individual if indispensable
Publication: DOI: 10.1111/bjh.18519
Treatment trends in MCL
Status: Completed
Type, Partner: Entity, Janssen
Year: 2019+
Type of analysis: Aggregated
Use of Lenalidomide in MCL treatment
Status: Closed
Type, Partner: Entity, Celgene
Year: 2017+
Key parameters: Number of patients treated with Lenalidomide for MCL
Type of analysis: Aggregated, Contact to treatment centers using drug
Fate of extranodal MCL
Status: Active
Type, Partner: Academic, FIL, EMCL-Verein
Year: 2016+
Key parameters: Extranodal manifestation
Type of analysis: Patient level